 Connection
Daniel Pollyea to Leukemia, Lymphocytic, Chronic, B-Cell
This is a "connection" page, showing publications Daniel Pollyea has written about Leukemia, Lymphocytic, Chronic, B-Cell.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.905 |
|
|
|
-
Kent A, Pollyea DA. Top advances of the year: Leukemia. Cancer. 2023 04 01; 129(7):981-985.
Score: 0.772
-
Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci U S A. 2017 09 05; 114(36):E7554-E7563.
Score: 0.133
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|